- Home
- RGC vs ORKA Comparison
RGC vs ORKA Comparison
Compare RGC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- ORKA
- Stock Information
- Founded
- RGC 2014
- ORKA 2004
- Country
- RGC Hong Kong
- ORKA United States
- Employees
- RGC N/A
- ORKA N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RGC Health Care
- ORKA Health Care
- Exchange
- RGC Nasdaq
- ORKA Nasdaq
- Market Cap
- RGC 377.5M
- ORKA 354.2M
- IPO Year
- RGC 2021
- ORKA N/A
- Fundamental
- Price
- RGC $38.01
- ORKA $11.74
- Analyst Decision
- RGC
- ORKA Strong Buy
- Analyst Count
- RGC 0
- ORKA 8
- Target Price
- RGC N/A
- ORKA $39.71
- AVG Volume (30 Days)
- RGC 1.5M
- ORKA 164.6K
- Earning Date
- RGC 07-01-2025
- ORKA 08-15-2025
- Dividend Yield
- RGC N/A
- ORKA N/A
- EPS Growth
- RGC N/A
- ORKA N/A
- EPS
- RGC N/A
- ORKA N/A
- Revenue
- RGC N/A
- ORKA N/A
- Revenue This Year
- RGC N/A
- ORKA N/A
- Revenue Next Year
- RGC N/A
- ORKA N/A
- P/E Ratio
- RGC N/A
- ORKA N/A
- Revenue Growth
- RGC N/A
- ORKA N/A
- 52 Week Low
- RGC $0.08
- ORKA $5.49
- 52 Week High
- RGC $83.60
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- RGC 56.71
- ORKA N/A
- Support Level
- RGC $15.12
- ORKA N/A
- Resistance Level
- RGC $83.60
- ORKA N/A
- Average True Range (ATR)
- RGC 10.44
- ORKA 0.00
- MACD
- RGC 3.76
- ORKA 0.00
- Stochastic Oscillator
- RGC 34.05
- ORKA 0.00
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.